- Total sales growth of 5.0% to $23.4
Billion with operational growth of 7.7%* and adjusted
operational growth of 7.9%*
- Earnings per share of $1.93
decreasing 16.8% and adjusted earnings per share of $2.67 increasing 3.1%*
- Company maintaining 2022 full-year guidance for adjusted
operational earnings per share and base business operational
sales
- Given global supply surplus and demand uncertainty, the Company
is suspending COVID-19 Vaccine sales guidance, with no impact to
adjusted operational earnings per share guidance
NEW
BRUNSWICK, N.J., April 19,
2022 /PRNewswire/ -- Johnson & Johnson (NYSE:
JNJ) today announced results for first-quarter 2022. "Our first
quarter results demonstrate strong performance across the
enterprise, despite macro-economic headwinds. I am incredibly proud
of Johnson & Johnson's 144,000 employees for their relentless
passion and Credo-based commitment to delivering transformative
healthcare solutions to patients and customers around the world,"
said Joaquin Duato, Chief Executive
Officer. "Looking ahead, I remain confident in the future of
Johnson & Johnson as we continue advancing our portfolio and
innovative pipeline."
OVERALL FINANCIAL
RESULTS
|
|
|
Q1
|
($ in Millions,
except EPS)
|
2022
|
2021
|
%
Change
|
Reported
Sales
|
$
23,426
|
$
22,321
|
5.0%
|
Net Earnings
|
5,149
|
6,197
|
(16.9)%
|
EPS
(diluted)
|
$
1.93
|
$
2.32
|
(16.8)%
|
|
|
|
|
|
Q1
|
Non-GAAP* ($ in
Millions, except EPS)
|
2022
|
2021
|
%
Change
|
Operational
Sales1,2
|
|
|
7.7%
|
Adjusted Operational
Sales1,3
|
|
|
7.9%
|
Adjusted Net
Earnings1,4
|
7,129
|
6,924
|
3.0%
|
Adjusted EPS
(diluted)1,4
|
$
2.67
|
$
2.59
|
3.1%
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial measures
included in accompanying schedules
|
2
|
Excludes the impact of
translational currency
|
3
|
Excludes the net impact
of acquisitions and divestitures and translational
currency
|
4
|
Excludes intangible
amortization expense and special items
|
|
Note: values may have
been rounded
|
REGIONAL SALES
RESULTS
|
|
Q1
|
|
%
Change
|
($ in
Millions)
|
2022
|
2021
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
U.S.
|
$ 11,414
|
$ 11,111
|
2.7%
|
2.7
|
-
|
2.8
|
International
|
12,012
|
11,210
|
7.2%
|
12.6
|
(5.4)
|
12.9
|
Worldwide
|
$ 23,426
|
$ 22,321
|
5.0%
|
7.7
|
(2.7)
|
7.9
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial measures
included in accompanying schedules
|
2
|
Excludes the impact of
translational currency
|
3
|
Excludes the net impact
of acquisitions and divestitures and translational
currency
|
|
Note: values may have
been rounded
|
SEGMENT SALES
RESULTS
|
|
Q1
|
|
%
Change
|
($ in
Millions)
|
2022
|
2021
|
Reported
|
Operational1,2
|
Currency
|
Adjusted
Operational1,3
|
Consumer
Health4
|
$
3,586
|
$
3,641
|
(1.5)%
|
0.8
|
(2.3)
|
1.6
|
Pharmaceutical4
|
12,869
|
12,101
|
6.3%
|
9.3
|
(3.0)
|
9.3
|
MedTech
|
6,971
|
6,579
|
5.9%
|
8.5
|
(2.6)
|
8.6
|
Worldwide
|
$
23,426
|
$ 22,321
|
5.0%
|
7.7
|
(2.7)
|
7.9
|
|
|
1
|
Non-GAAP financial
measure; refer to reconciliations of non-GAAP financial measures
included in accompanying schedules
|
2
|
Excludes the impact of
translational currency
|
3
|
Excludes the net impact
of acquisitions and divestitures and translational
currency
|
4
|
Certain international
OTC products, primarily in China, were reclassified from the
Pharmaceutical segment to the Consumer Health segment based on
operational changes in their respective
regions
|
|
Note: The MedTech
segment was previously referred to as the Medical Devices
segment
|
|
Values may have been rounded
|
FIRST QUARTER 2022 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide adjusted
operational sales, which exclude the net impact of acquisitions and
divestitures and translational currency, increased 1.6%* primarily
driven by over-the-counter (OTC) products. Major contributors to
growth in OTC were upper respiratory products, TYLENOL and MOTRIN
analgesics, and IMODIUM in digestive health products. Growth was
partially offset by external supply constraints mainly impacting
Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide adjusted
operational sales, which exclude the net impact of acquisitions and
divestitures and translational currency, grew 9.3%* driven by
DARZALEX (daratumumab), a biologic for the treatment of multiple
myeloma, STELARA (ustekinumab), a biologic for the treatment of a
number of immune-mediated inflammatory diseases, TREMFYA
(guselkumab), a biologic for the treatment of adults living with
moderate to severe plaque psoriasis, and for adults with active
psoriatic arthritis, ERLEADA (apalutamide), a next-generation
androgen receptor inhibitor for the treatment of patients with
prostate cancer, and INVEGA SUSTENNA/XEPLION and INVEGA
TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable
atypical antipsychotics for the treatment of schizophrenia in
adults. Also contributing to growth were sales of the Janssen
COVID-19 Vaccine (Ad26.COV2.S) for the prevention of the SARS-CoV-2
virus. This growth was partially offset by declines in sales of
REMICADE (infliximab), a biologic approved for the treatment of a
number of immune-mediated inflammatory diseases, XARELTO
(rivaroxaban), a direct oral anticoagulant, and ZYTIGA (abiratone
acetate), an oral, once-daily medication for use in combination
with prednisone for the treatment of metastatic
castration-resistant prostate cancer.
MedTech
MedTech worldwide adjusted operational sales,
which exclude the net impact of acquisitions and divestitures and
translational currency, grew 8.6%*, driven by electrophysiology
products in Interventional Solutions, contact lenses and surgical
vision products in Vision, wound closure products in General
Surgery, biosurgery in Advanced Surgery, and hips, trauma, and
knees in Orthopaedics.
NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The
information contained in this section should be read in conjunction
with Johnson & Johnson's other disclosures filed with the
Securities and Exchange Commission, including its Current Reports
on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on
Form 10-K. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
The reader is also encouraged to review all other news releases and
information available in the Investors section of the company's
website at news releases, as well as
www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com,
and www.LTLManagementInformation.com.
Regulatory
Decisions
|
U.S. FDA Approves
CARVYKTI (ciltacabtagene autoleucel), Janssen's First Cell Therapy,
a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients
with Relapsed or Refractory Multiple Myeloma
|
(press
release)
|
U.S. FDA Approves
CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months,
Expanding the Label of the First and Only Long-Acting HIV
Treatment
|
(press
release)
|
U.S. FDA Approves
CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding
the Indication of the First and Only Complete Long-Acting
Injectable HIV Regimen1
|
(press
release)
|
U.S. FDA Approves
Streamlined Process for Initiating HIV Therapy with CABENUVA
(cabotegravir and rilpivirine), the First and Only Complete
Long-Acting Injectable HIV Treatment
|
(press
release)
|
Regulatory
Submissions
|
Janssen Submits
Marketing Authorisation Application to the European Medicines
Agency Seeking Approval of Bispecific Antibody Teclistamab for the
Treatment of Patients with Relapsed or Refractory Multiple
Myeloma
|
(press
release)
|
Janssen Seeks Approval
of a New Indication for IMBRUVICA (ibrutinib) for Use in Patients
with Untreated Mantle Cell Lymphoma
|
(press
release)
|
Other
|
Janssen Presents New
Data Demonstrating the Combination of Niraparib and Abiraterone
Acetate Plus Prednisone Significantly Improved Radiographic
Progression-Free Survival as a First-Line Therapy in Patients with
HRR Gene-Mutated Metastatic Castration-Resistant Prostate
Cancer
|
(press
release)
|
Johnson & Johnson
Statement on Nationwide Opioid Settlement Agreement
|
(press
release)
|
DePuy Synthes Further
Reimagines Knee Restoration with the Addition of Two New
Innovations to the ATTUNE Knee Portfolio
|
(press
release)
|
Janssen Initiates
First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care
for People of Color with Moderate to Severe Plaque
Psoriasis
|
(press
release)
|
Johnson & Johnson
Statement on War in Ukraine
|
(press
release)
|
1Subsequent
to the quarter
|
FULL-YEAR 2022 GUIDANCE:
Johnson & Johnson does
not provide GAAP financial measures on a forward-looking basis
because the company is unable to predict with reasonable certainty
the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair
value adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
Please note that the Company has suspended guidance on its
COVID-19 Vaccine sales. The table below excludes COVID-19 Vaccine
sales from Adjusted Operational Sales, Operational Sales, and
Estimated Reported Sales.
($ in Billions,
except
EPS)
|
April
2022
|
January
2022
|
Adjusted Operational
Sales1,2,5
Change vs. Prior
Year
|
6.5% – 7.5%
|
6.5% – 7.5%
|
Operational
Sales2,5
Change vs. Prior
Year
|
$97.3B –
$98.3B
6.5% – 7.5%
|
$97.3B –
$98.3B
6.5% – 7.5%
|
Estimated Reported
Sales3,5
Change vs. Prior
Year
|
$94.8B –
$95.8B
3.8% – 4.8%
|
$95.9B -
$96.9B
5.0% – 6.0%
|
|
|
|
Adjusted Operational
EPS (Diluted)2,4
Change vs. Prior
Year
|
$10.60 -
$10.80
8.2% – 10.2%
|
$10.60 -
$10.80
8.2% – 10.2%
|
Adjusted EPS
(Diluted)3,4
Change vs. Prior
Year
|
$10.15 -
$10.35
3.6% – 5.6%
|
$10.40 -
$10.60
6.1% – 8.2%
|
|
|
1
|
Non-GAAP financial
measure; excludes the net impact of acquisitions and
divestitures
|
2
|
Non-GAAP financial
measure; excludes the impact of translational currency
|
3
|
Calculated using Euro
Average Rate: January 2022 = $1.14 and April = $1.09 (Illustrative
purposes only)
|
4
|
Non-GAAP financial
measure; excludes intangible amortization expense and special
items
|
5
|
Excludes COVID-19
Vaccine
|
|
Note: percentages may
have been rounded
|
Other modeling considerations will be provided on the
webcast.
WEBCAST INFORMATION:
Johnson & Johnson will
conduct a conference call with investors to discuss this earnings
release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and
other interested parties may be accessed by visiting the Johnson
& Johnson website. A replay and podcast will be available
approximately two hours after the live webcast in the Investors
section of the company's website at
events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NON-GAAP FINANCIAL MEASURES:
* "Operational sales
growth" excluding the impact of translational currency, "adjusted
operational sales growth" excluding the net impact of acquisitions
and divestitures and translational currency, as well as "adjusted
net earnings", "adjusted diluted earnings per share" and "adjusted
operational diluted earnings per share" excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings
release are available on the company's website at
quarterly-results. These schedules include supplementary sales
data, a condensed consolidated statement of earnings,
reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson &
Johnson, including adjusted income before tax by segment, a
pharmaceutical pipeline of selected compounds in late stage
development and a copy of today's earnings call presentation can
also be found in the Investors section of the company's website at
quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating and
financial performance, product development, market position and
business strategy, and the anticipated separation of the Company's
Consumer Health business. The reader is cautioned not to rely on
these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions
prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors,
such as interest rate and currency exchange rate fluctuations;
competition, including technological advances, new products and
patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success
and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to
successfully execute strategic plans; the impact of business
combinations and divestitures; manufacturing difficulties or
delays, internally or within the supply chain; product efficacy or
safety concerns resulting in product recalls or regulatory action;
significant adverse litigation or government action, including
related to product liability claims; changes to applicable laws and
regulations, including tax laws and global health care reforms;
trends toward health care cost containment; changes in behavior and
spending patterns of purchasers of health care products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies; the Company's ability to
satisfy the necessary conditions to consummate the separation of
the Company's Consumer Health business on a timely basis or at all;
the Company's ability to successfully separate the Company's
Consumer Health business and realize the anticipated benefits from
the separation; the New Consumer Health Company's ability to
succeed as a standalone publicly traded company; and risks related
to the impact of the COVID-19 global pandemic, such as the scope
and duration of the outbreak, government actions and restrictive
measures implemented in response, material delays and cancellations
of medical procedures, supply chain disruptions and other impacts
to the business, or on the company's ability to execute business
continuity plans, as a result of the COVID-19 pandemic. A further
list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January
2, 2022, including in the sections captioned "Cautionary
Note Regarding Forward-Looking Statements" and "Item 1A. Risk
Factors," and in Johnson & Johnson's subsequent Quarterly
Reports on Form 10-Q and other filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward-looking statement made in this release speaks
only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Supplementary Sales
Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars in
Millions)
|
FIRST
QUARTER
|
|
|
|
|
|
Percent
Change
|
|
2022
|
|
2021
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Health
(1)
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,557
|
|
1,611
|
|
(3.4)
|
%
|
(3.4)
|
|
-
|
International
|
2,029
|
|
2,030
|
|
0.0
|
|
4.1
|
|
(4.1)
|
|
3,586
|
|
3,641
|
|
(1.5)
|
|
0.8
|
|
(2.3)
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
(1)
|
|
|
|
|
|
|
|
|
|
U.S.
|
6,632
|
|
6,446
|
|
2.9
|
|
2.9
|
|
-
|
International
|
6,237
|
|
5,655
|
|
10.3
|
|
16.7
|
|
(6.4)
|
|
12,869
|
|
12,101
|
|
6.3
|
|
9.3
|
|
(3.0)
|
|
|
|
|
|
|
|
|
|
|
MedTech
(2)
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,225
|
|
3,054
|
|
5.6
|
|
5.6
|
|
-
|
International
|
3,746
|
|
3,525
|
|
6.3
|
|
11.1
|
|
(4.8)
|
|
6,971
|
|
6,579
|
|
5.9
|
|
8.5
|
|
(2.6)
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
11,414
|
|
11,111
|
|
2.7
|
|
2.7
|
|
-
|
International
|
12,012
|
|
11,210
|
|
7.2
|
|
12.6
|
|
(5.4)
|
Worldwide
|
$
23,426
|
|
22,321
|
|
5.0
|
%
|
7.7
|
|
(2.7)
|
|
|
|
|
|
|
|
|
|
|
Note: Percentages have been calculated using actual,
non-rounded figures and, therefore, may not recalculate
precisely.
|
|
|
(1)
Certain international OTC products,
primarily in China, were reclassified from the Pharmaceutical
segment to the Consumer Health segment based on operational
changes in their respective regions
|
(2)
Previously referred to as Medical Devices
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Supplementary Sales
Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars in
Millions)
|
FIRST
QUARTER
|
|
|
|
|
|
Percent
Change
|
|
2022
|
|
2021
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
11,414
|
|
11,111
|
|
2.7
|
%
|
2.7
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Europe
|
6,024
|
|
5,414
|
|
11.3
|
|
19.5
|
|
(8.2)
|
Western Hemisphere
excluding U.S.
|
1,482
|
|
1,424
|
|
4.1
|
|
5.1
|
|
(1.0)
|
Asia-Pacific,
Africa
|
4,506
|
|
4,372
|
|
3.1
|
|
6.6
|
|
(3.5)
|
International
|
12,012
|
|
11,210
|
|
7.2
|
|
12.6
|
|
(5.4)
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
23,426
|
|
22,321
|
|
5.0
|
%
|
7.7
|
|
(2.7)
|
|
|
|
|
|
|
|
|
|
|
Note: Percentages have been calculated using actual,
non-rounded figures and, therefore, may not recalculate
precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
FIRST
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2022
|
|
2021
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
23,426
|
|
100.0
|
|
$
22,321
|
|
100.0
|
|
5.0
|
Cost of products
sold
|
7,598
|
|
32.4
|
|
7,063
|
|
31.7
|
|
7.6
|
Gross
Profit
|
15,828
|
|
67.6
|
|
15,258
|
|
68.3
|
|
3.7
|
Selling, marketing
and administrative expenses
|
5,938
|
|
25.4
|
|
5,432
|
|
24.3
|
|
9.3
|
Research and
development expense
|
3,462
|
|
14.8
|
|
3,178
|
|
14.2
|
|
8.9
|
In-process research
and development
|
610
|
|
2.6
|
|
-
|
|
-
|
|
|
Interest (income)
expense, net
|
(12)
|
|
(0.1)
|
|
48
|
|
0.2
|
|
|
Other (income)
expense, net
|
(102)
|
|
(0.4)
|
|
(882)
|
|
(3.9)
|
|
|
Restructuring
|
70
|
|
0.3
|
|
53
|
|
0.2
|
|
|
Earnings before
provision for taxes on income
|
5,862
|
|
25.0
|
|
7,429
|
|
33.3
|
|
(21.1)
|
Provision for taxes
on income
|
713
|
|
3.0
|
|
1,232
|
|
5.5
|
|
(42.1)
|
Net
earnings
|
5,149
|
|
22.0
|
|
6,197
|
|
27.8
|
|
(16.9)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.93
|
|
|
|
$
2.32
|
|
|
|
(16.8)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,666.5
|
|
|
|
2,672.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
12.2
|
%
|
|
|
16.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings (1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
8,218
|
|
35.1
|
|
$
8,291
|
|
37.1
|
|
(0.9)
|
Net
earnings
|
$
7,129
|
|
30.4
|
|
$
6,924
|
|
31.0
|
|
3.0
|
Net earnings per
share (Diluted)
|
$
2.67
|
|
|
|
$
2.59
|
|
|
|
3.1
|
Effective tax
rate
|
13.3
|
%
|
|
|
16.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
See Reconciliation of Non-GAAP Financial
Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
First
Quarter
|
|
(Dollars in Millions
Except Per Share Data)
|
|
2022
|
|
2021
|
|
Net Earnings, after
tax- as reported
|
|
$5,149
|
|
$6,197
|
|
|
|
|
|
|
|
Pre-tax
Adjustments
|
|
|
|
|
|
Intangible Asset
Amortization expense
|
|
1,108
|
|
1,215
|
|
IPR&D
|
|
610
|
|
-
|
|
Restructuring
related
|
|
72
|
|
104
|
|
Acquisition,
integration and divestiture related ¹
|
|
-
|
|
(538)
|
|
(Gains)/losses on
securities
|
|
411
|
|
35
|
|
Medical Device
Regulation 2
|
|
60
|
|
46
|
|
Consumer Health
separation costs
|
|
102
|
|
-
|
|
Other
|
|
(7)
|
|
-
|
|
|
|
|
|
|
|
Tax
Adjustments
|
|
|
|
|
|
Tax impact on special
item adjustments 3
|
|
(393)
|
|
(113)
|
|
Consumer Health
separation tax related costs
|
|
96
|
|
-
|
|
Tax legislation and
other tax related
|
|
(79)
|
|
(22)
|
|
Adjusted Net Earnings,
after tax
|
|
$7,129
|
|
$6,924
|
|
Average shares
outstanding (Diluted)
|
|
2,666.5
|
|
2,672.7
|
|
Adjusted net earnings
per share (Diluted)
|
|
$2.67
|
|
$2.59
|
|
Operational adjusted
net earnings per share (Diluted)
|
|
$2.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
1
|
Acquisition,
integration and divestiture related for the first quarter of 2021
primarily includes the gain on the divestiture of 2 Pharmaceutical
brands outside of the U.S.
|
2
|
European Medical Device
Regulation (MDR) costs represent one-time compliance costs for the
Company's previously registered products. MDR is a replacement of
the existing European Medical Devices Directive regulatory
framework, and manufacturers of currently marketed medical devices
were required to comply with EU MDR beginning in May 2021. The
Company considers the adoption of EU MDR to be a significant
one-time regulatory change and is not indicative of on-going
operations. The Company has excluded only external
third-party regulatory and consulting costs from its MedTech
operating segments' measures of profit and loss used for making
operating decisions and assessing performance which is expected to
be completed by the end of 2023.
|
3
|
The tax impact related
to special item adjustments reflects the current and deferred
income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operational
Sales Growth
|
FIRST QUARTER
2022 ACTUAL vs. 2021 ACTUAL
|
|
Segments
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
MedTech
|
|
Total
|
WW As
Reported
|
|
(1.5)%
|
|
6.3%
|
|
5.9%
|
|
5.0%
|
U.S.
|
|
(3.4)%
|
|
2.9%
|
|
5.6%
|
|
2.7%
|
International
|
|
0.0%
|
|
10.3%
|
|
6.3%
|
|
7.2%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
(2.3)
|
|
(3.0)
|
|
(2.6)
|
|
(2.7)
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
(4.1)
|
|
(6.4)
|
|
(4.8)
|
|
(5.4)
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
0.8%
|
|
9.3%
|
|
8.5%
|
|
7.7%
|
U.S.
|
|
(3.4)%
|
|
2.9%
|
|
5.6%
|
|
2.7%
|
International
|
|
4.1%
|
|
16.7%
|
|
11.1%
|
|
12.6%
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Sedona
|
|
0.6
|
|
|
|
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
1.1
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.2
|
|
0.0
|
|
0.1
|
|
0.1
|
U.S.
|
|
0.2
|
|
0.0
|
|
0.1
|
|
0.1
|
International
|
|
0.1
|
|
0.0
|
|
0.1
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
1.6%
|
|
9.3%
|
|
8.6%
|
|
7.9%
|
U.S.
|
|
(3.2)%
|
|
2.9%
|
|
5.7%
|
|
2.8%
|
International
|
|
5.3%
|
|
16.7%
|
|
11.2%
|
|
12.9%
|
|
|
|
|
|
|
|
|
|
Note: Percentages are based on actual, non-rounded figures
and may not sum.
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER HEALTH
SEGMENT (2,3)
|
|
|
|
|
|
|
|
OTC (5)
|
|
|
|
|
|
|
|
US
|
|
$
670
|
|
599
|
11.8%
|
11.8%
|
-
|
Intl
|
|
791
|
|
673
|
17.5%
|
21.7%
|
-4.2%
|
WW
|
|
1,461
|
|
1,273
|
14.8%
|
17.1%
|
-2.3%
|
SKIN HEALTH /
BEAUTY
|
|
|
|
|
|
|
|
US
|
|
544
|
|
634
|
-14.2%
|
-14.2%
|
-
|
Intl
|
|
468
|
|
529
|
-11.6%
|
-7.1%
|
-4.5%
|
WW
|
|
1,012
|
|
1,163
|
-13.0%
|
-11.0%
|
-2.0%
|
ORAL CARE
|
|
|
|
|
|
|
|
US
|
|
143
|
|
163
|
-12.6%
|
-12.6%
|
-
|
Intl
|
|
223
|
|
254
|
-12.0%
|
-8.6%
|
-3.4%
|
WW
|
|
366
|
|
417
|
-12.2%
|
-10.2%
|
-2.0%
|
BABY CARE
|
|
|
|
|
|
|
|
US
|
|
85
|
|
96
|
-11.5%
|
-11.5%
|
-
|
Intl
|
|
270
|
|
293
|
-7.7%
|
-4.8%
|
-2.9%
|
WW
|
|
355
|
|
389
|
-8.6%
|
-6.4%
|
-2.2%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
US
|
|
3
|
|
3
|
7.2%
|
7.2%
|
-
|
Intl
|
|
224
|
|
219
|
2.5%
|
8.3%
|
-5.8%
|
WW
|
|
228
|
|
222
|
2.6%
|
8.3%
|
-5.7%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
US
|
|
112
|
|
115
|
-3.3%
|
-3.3%
|
-
|
Intl
|
|
52
|
|
61
|
-15.3%
|
-14.5%
|
-0.8%
|
WW
|
|
164
|
|
177
|
-7.4%
|
-7.2%
|
-0.2%
|
|
|
|
|
|
|
|
|
TOTAL CONSUMER
HEALTH
|
|
|
|
|
|
|
|
US
|
|
1,557
|
|
1,611
|
-3.4%
|
-3.4%
|
-
|
Intl
|
|
2,029
|
|
2,030
|
0.0%
|
4.1%
|
-4.1%
|
WW
|
|
$
3,586
|
|
3,641
|
-1.5%
|
0.8%
|
-2.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end of
schedule
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
PHARMACEUTICAL
SEGMENT (2,3)
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
US
|
|
$
2,501
|
|
2,413
|
3.7%
|
3.7%
|
-
|
Intl
|
|
1,617
|
|
1,501
|
7.7%
|
13.7%
|
-6.0%
|
WW
|
|
4,119
|
|
3,914
|
5.2%
|
7.5%
|
-2.3%
|
REMICADE
|
|
|
|
|
|
|
|
US
|
|
358
|
|
489
|
-26.8%
|
-26.8%
|
-
|
US Exports
(4)
|
|
80
|
|
57
|
40.5%
|
40.5%
|
-
|
Intl
|
|
225
|
|
232
|
-2.6%
|
-1.0%
|
-1.6%
|
WW
|
|
663
|
|
777
|
-14.7%
|
-14.2%
|
-0.5%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
US
|
|
287
|
|
255
|
12.5%
|
12.5%
|
-
|
Intl
|
|
283
|
|
307
|
-7.6%
|
-1.9%
|
-5.7%
|
WW
|
|
571
|
|
562
|
1.5%
|
4.7%
|
-3.2%
|
STELARA
|
|
|
|
|
|
|
|
US
|
|
1,379
|
|
1,331
|
3.6%
|
3.6%
|
-
|
Intl
|
|
909
|
|
817
|
11.2%
|
17.8%
|
-6.6%
|
WW
|
|
2,288
|
|
2,148
|
6.5%
|
9.0%
|
-2.5%
|
TREMFYA
|
|
|
|
|
|
|
|
US
|
|
391
|
|
274
|
42.7%
|
42.7%
|
-
|
Intl
|
|
199
|
|
143
|
38.8%
|
47.9%
|
-9.1%
|
WW
|
|
590
|
|
418
|
41.3%
|
44.5%
|
-3.2%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
US
|
|
6
|
|
7
|
-3.2%
|
-3.2%
|
-
|
Intl
|
|
0
|
|
2
|
*
|
*
|
*
|
WW
|
|
6
|
|
8
|
-22.0%
|
-22.0%
|
-
|
INFECTIOUS DISEASES
(5)
|
|
|
|
|
|
|
|
US
|
|
461
|
|
512
|
-10.0%
|
-10.0%
|
-
|
Intl
|
|
836
|
|
485
|
72.3%
|
78.6%
|
-6.3%
|
WW
|
|
1,297
|
|
998
|
30.0%
|
33.1%
|
-3.1%
|
COVID-19
VACCINE
|
|
|
|
|
|
|
|
US
|
|
75
|
|
100
|
-24.9%
|
-24.9%
|
-
|
Intl
|
|
382
|
|
0
|
*
|
*
|
*
|
WW
|
|
457
|
|
100
|
*
|
*
|
*
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
US
|
|
9
|
|
10
|
-12.6%
|
-12.6%
|
-
|
Intl
|
|
239
|
|
233
|
2.5%
|
10.5%
|
-8.0%
|
WW
|
|
248
|
|
243
|
1.8%
|
9.6%
|
-7.8%
|
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
US
|
|
369
|
|
380
|
-3.1%
|
-3.1%
|
-
|
Intl
|
|
132
|
|
166
|
-20.3%
|
-15.9%
|
-4.4%
|
WW
|
|
501
|
|
546
|
-8.3%
|
-6.9%
|
-1.4%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
US
|
|
8
|
|
21
|
-62.5%
|
-62.5%
|
-
|
Intl
|
|
83
|
|
87
|
-3.8%
|
1.6%
|
-5.4%
|
WW
|
|
91
|
|
108
|
-15.3%
|
-11.0%
|
-4.3%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
(5)
|
|
|
|
|
|
|
|
US
|
|
843
|
|
771
|
9.3%
|
9.3%
|
-
|
Intl
|
|
898
|
|
943
|
-4.8%
|
1.5%
|
-6.3%
|
WW
|
|
1,741
|
|
1,715
|
1.5%
|
5.0%
|
-3.5%
|
CONCERTA /
Methylphenidate
|
|
|
|
|
|
|
|
US
|
|
35
|
|
47
|
-26.5%
|
-26.5%
|
-
|
Intl
|
|
122
|
|
123
|
-1.3%
|
3.5%
|
-4.8%
|
WW
|
|
157
|
|
171
|
-8.3%
|
-4.8%
|
-3.5%
|
INVEGA SUSTENNA /
XEPLION /
INVEGA TRINZA / TREVICTA
|
|
|
|
|
|
|
|
US
|
|
661
|
|
589
|
12.2%
|
12.2%
|
-
|
Intl
|
|
387
|
|
376
|
3.0%
|
9.9%
|
-6.9%
|
WW
|
|
1,048
|
|
965
|
8.6%
|
11.3%
|
-2.7%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
US
|
|
63
|
|
67
|
-6.4%
|
-6.4%
|
-
|
Intl
|
|
66
|
|
89
|
-26.1%
|
-19.6%
|
-6.5%
|
WW
|
|
129
|
|
157
|
-17.6%
|
-13.9%
|
-3.7%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
US
|
|
84
|
|
67
|
25.5%
|
25.5%
|
-
|
Intl
|
|
323
|
|
355
|
-8.9%
|
-2.8%
|
-6.1%
|
WW
|
|
408
|
|
422
|
-3.5%
|
1.7%
|
-5.2%
|
ONCOLOGY
|
|
|
|
|
|
|
|
US
|
|
1,582
|
|
1,377
|
14.9%
|
14.9%
|
-
|
Intl
|
|
2,369
|
|
2,193
|
8.0%
|
15.0%
|
-7.0%
|
WW
|
|
3,950
|
|
3,570
|
10.6%
|
14.9%
|
-4.3%
|
DARZALEX
|
|
|
|
|
|
|
|
US
|
|
953
|
|
691
|
37.9%
|
37.9%
|
-
|
Intl
|
|
903
|
|
674
|
34.0%
|
42.7%
|
-8.7%
|
WW
|
|
1,856
|
|
1,365
|
36.0%
|
40.3%
|
-4.3%
|
ERLEADA
|
|
|
|
|
|
|
|
US
|
|
206
|
|
171
|
20.3%
|
20.3%
|
-
|
Intl
|
|
194
|
|
90
|
*
|
*
|
*
|
WW
|
|
400
|
|
261
|
53.0%
|
57.5%
|
-4.5%
|
IMBRUVICA
|
|
|
|
|
|
|
|
US
|
|
370
|
|
444
|
-16.7%
|
-16.7%
|
-
|
Intl
|
|
668
|
|
680
|
-1.8%
|
4.5%
|
-6.3%
|
WW
|
|
1,038
|
|
1,125
|
-7.7%
|
-3.9%
|
-3.8%
|
ZYTIGA / abiraterone
acetate
|
|
|
|
|
|
|
|
US
|
|
19
|
|
50
|
-62.1%
|
-62.1%
|
-
|
Intl
|
|
520
|
|
588
|
-11.6%
|
-5.7%
|
-5.9%
|
WW
|
|
539
|
|
638
|
-15.6%
|
-10.1%
|
-5.5%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
US
|
|
34
|
|
21
|
63.1%
|
63.1%
|
-
|
Intl
|
|
84
|
|
161
|
-47.7%
|
-44.6%
|
-3.1%
|
WW
|
|
118
|
|
182
|
-35.1%
|
-32.3%
|
-2.8%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
US
|
|
572
|
|
573
|
-0.2%
|
-0.2%
|
-
|
Intl
|
|
279
|
|
288
|
-2.9%
|
4.0%
|
-6.9%
|
WW
|
|
852
|
|
861
|
-1.1%
|
1.2%
|
-2.3%
|
OPSUMIT
|
|
|
|
|
|
|
|
US
|
|
273
|
|
272
|
0.5%
|
0.5%
|
-
|
Intl
|
|
170
|
|
179
|
-4.8%
|
2.0%
|
-6.8%
|
WW
|
|
443
|
|
450
|
-1.6%
|
1.1%
|
-2.7%
|
UPTRAVI
|
|
|
|
|
|
|
|
US
|
|
269
|
|
259
|
3.9%
|
3.9%
|
-
|
Intl
|
|
56
|
|
46
|
20.9%
|
28.8%
|
-7.9%
|
WW
|
|
325
|
|
305
|
6.5%
|
7.7%
|
-1.2%
|
OTHER PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
US
|
|
30
|
|
42
|
-29.0%
|
-29.0%
|
-
|
Intl
|
|
53
|
|
63
|
-15.2%
|
-8.4%
|
-6.8%
|
WW
|
|
83
|
|
105
|
-20.8%
|
-16.8%
|
-4.0%
|
CARDIOVASCULAR /
METABOLISM / OTHER (5)
|
|
|
|
|
|
|
|
US
|
|
672
|
|
799
|
-15.8%
|
-15.8%
|
-
|
Intl
|
|
238
|
|
245
|
-3.0%
|
0.9%
|
-3.9%
|
WW
|
|
910
|
|
1,044
|
-12.8%
|
-11.9%
|
-0.9%
|
XARELTO
|
|
|
|
|
|
|
|
US
|
|
508
|
|
589
|
-13.8%
|
-13.8%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
508
|
|
589
|
-13.8%
|
-13.8%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
US
|
|
60
|
|
87
|
-30.7%
|
-30.7%
|
-
|
Intl
|
|
68
|
|
63
|
7.5%
|
11.1%
|
-3.6%
|
WW
|
|
128
|
|
150
|
-14.6%
|
-13.1%
|
-1.5%
|
OTHER
|
|
|
|
|
|
|
|
US
|
|
104
|
|
122
|
-14.9%
|
-14.9%
|
-
|
Intl
|
|
170
|
|
182
|
-6.6%
|
-2.6%
|
-4.0%
|
WW
|
|
274
|
|
305
|
-10.0%
|
-7.5%
|
-2.5%
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
US
|
|
6,632
|
|
6,446
|
2.9%
|
2.9%
|
-
|
Intl
|
|
6,237
|
|
5,655
|
10.3%
|
16.7%
|
-6.4%
|
WW
|
|
$
12,869
|
|
12,101
|
6.3%
|
9.3%
|
-3.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end of
schedule
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
FIRST
QUARTER
|
|
|
|
|
|
%
Change
|
MEDTECH SEGMENT
(2,3,6)
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
US
|
|
$
494
|
|
434
|
13.8%
|
13.8%
|
-
|
Intl
|
|
597
|
|
514
|
16.2%
|
20.4%
|
-4.2%
|
WW
|
|
1,092
|
|
949
|
15.1%
|
17.4%
|
-2.3%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
US
|
|
1,289
|
|
1,249
|
3.2%
|
3.2%
|
-
|
Intl
|
|
899
|
|
864
|
4.1%
|
9.1%
|
-5.0%
|
WW
|
|
2,188
|
|
2,113
|
3.5%
|
5.6%
|
-2.1%
|
HIPS
|
|
|
|
|
|
|
|
US
|
|
225
|
|
209
|
7.3%
|
7.3%
|
-
|
Intl
|
|
164
|
|
146
|
12.2%
|
17.0%
|
-4.8%
|
WW
|
|
389
|
|
356
|
9.3%
|
11.3%
|
-2.0%
|
KNEES
|
|
|
|
|
|
|
|
US
|
|
201
|
|
185
|
8.6%
|
8.6%
|
-
|
Intl
|
|
138
|
|
132
|
4.1%
|
9.1%
|
-5.0%
|
WW
|
|
339
|
|
317
|
6.7%
|
8.8%
|
-2.1%
|
TRAUMA
|
|
|
|
|
|
|
|
US
|
|
475
|
|
450
|
5.5%
|
5.5%
|
-
|
Intl
|
|
273
|
|
282
|
-3.3%
|
2.2%
|
-5.5%
|
WW
|
|
748
|
|
733
|
2.1%
|
4.2%
|
-2.1%
|
SPINE, SPORTS &
OTHER
|
|
|
|
|
|
|
|
US
|
|
387
|
|
404
|
-4.1%
|
-4.1%
|
-
|
Intl
|
|
324
|
|
303
|
7.0%
|
11.7%
|
-4.7%
|
WW
|
|
712
|
|
707
|
0.6%
|
2.7%
|
-2.1%
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
FIRST
QUARTER
|
|
|
|
|
|
|
%
Change
|
|
|
|
2022
|
|
2021
|
Reported
|
Operational
(1)
|
Currency
|
|
SURGERY
|
|
|
|
|
|
|
|
|
US
|
|
921
|
|
898
|
2.5%
|
2.5%
|
-
|
|
Intl
|
|
1,513
|
|
1,474
|
2.7%
|
6.6%
|
-3.9%
|
|
WW
|
|
2,434
|
|
2,372
|
2.6%
|
5.0%
|
-2.4%
|
|
ADVANCED
|
|
|
|
|
|
|
|
|
US
|
|
417
|
|
405
|
3.0%
|
3.0%
|
-
|
|
Intl
|
|
729
|
|
713
|
2.2%
|
5.4%
|
-3.2%
|
|
WW
|
|
1,146
|
|
1,118
|
2.5%
|
4.5%
|
-2.0%
|
|
GENERAL
|
|
|
|
|
|
|
|
|
US
|
|
504
|
|
493
|
2.1%
|
2.1%
|
-
|
|
Intl
|
|
784
|
|
761
|
3.1%
|
7.7%
|
-4.6%
|
|
WW
|
|
1,288
|
|
1,254
|
2.7%
|
5.5%
|
-2.8%
|
|
VISION
|
|
|
|
|
|
|
|
|
US
|
|
521
|
|
472
|
10.4%
|
10.4%
|
-
|
|
Intl
|
|
736
|
|
673
|
9.4%
|
16.4%
|
-7.0%
|
|
WW
|
|
1,257
|
|
1,145
|
9.8%
|
13.9%
|
-4.1%
|
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
|
US
|
|
400
|
|
371
|
7.7%
|
7.7%
|
-
|
|
Intl
|
|
511
|
|
486
|
5.1%
|
12.9%
|
-7.8%
|
|
WW
|
|
910
|
|
857
|
6.2%
|
10.6%
|
-4.4%
|
|
SURGICAL
|
|
|
|
|
|
|
|
|
US
|
|
121
|
|
101
|
20.2%
|
20.2%
|
-
|
|
Intl
|
|
226
|
|
187
|
20.5%
|
25.7%
|
-5.2%
|
|
WW
|
|
347
|
|
288
|
20.4%
|
23.8%
|
-3.4%
|
|
|
|
|
|
|
|
|
|
|
TOTAL
MEDTECH
|
|
|
|
|
|
|
|
|
US
|
|
3,225
|
|
3,054
|
5.6%
|
5.6%
|
-
|
|
Intl
|
|
3,746
|
|
3,525
|
6.3%
|
11.1%
|
-4.8%
|
|
WW
|
|
$
6,971
|
|
6,579
|
5.9%
|
8.5%
|
-2.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Columns and rows within tables may not
add due to rounding. Percentages have been calculated using actual,
non-rounded figures and,
therefore, may not recalculate precisely.
|
|
* Percentage greater
than 100% or not meaningful
|
|
|
|
|
|
|
|
|
(1) Operational growth
excludes the effect of translational currency
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
(3) Certain prior year
amounts have been reclassified to conform to current year product
disclosures
|
|
(4) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
(5) Refer to
supplemental sales information schedule
|
|
(6) Previously referred
to as Medical Devices
|
|
|
|
|
|
|
|
|
Supplemental Sales
Information
|
(Dollars in
Millions)
|
Certain prior year
amounts have been reclassified to
|
conform to current year
product disclosures
|
|
|
2020
|
|
2021
|
|
2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full
Year
|
|
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
|
|
Full
Year
|
|
|
|
CONSUMER HEALTH
SEGMENT (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
2,460
|
|
|
|
599
|
|
675
|
|
686
|
|
633
|
|
|
|
2,594
|
|
|
|
Intl
|
|
2,761
|
|
|
|
673
|
|
752
|
|
798
|
|
811
|
|
|
|
3,034
|
|
|
|
WW
|
|
5,221
|
|
|
|
1,273
|
|
1,426
|
|
1,484
|
|
1,444
|
|
|
|
5,627
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PHARMACEUTICAL
SEGMENT (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INFECTIOUS DISEASES
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
104
|
|
|
|
21
|
|
16
|
|
18
|
|
11
|
|
|
|
66
|
|
|
|
Intl
|
|
292
|
|
|
|
87
|
|
71
|
|
82
|
|
57
|
|
|
|
297
|
|
|
|
WW
|
|
396
|
|
|
|
108
|
|
88
|
|
99
|
|
68
|
|
|
|
363
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NEUROSCIENCE
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
298
|
|
|
|
67
|
|
91
|
|
81
|
|
99
|
|
|
|
338
|
|
|
|
Intl
|
|
1,312
|
|
|
|
355
|
|
373
|
|
298
|
|
342
|
|
|
|
1,368
|
|
|
|
WW
|
|
1,610
|
|
|
|
422
|
|
464
|
|
379
|
|
441
|
|
|
|
1,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDIOVASCULAR /
METABOLISM / OTHER (2,3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
600
|
|
|
|
122
|
|
116
|
|
98
|
|
110
|
|
|
|
446
|
|
|
|
Intl
|
|
794
|
|
|
|
182
|
|
178
|
|
173
|
|
140
|
|
|
|
673
|
|
|
|
WW
|
|
1,394
|
|
|
|
305
|
|
293
|
|
271
|
|
250
|
|
|
|
1,119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note : Columns and rows within
tables may not add due to rounding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Certain
international OTC products, primarily in China, were reclassified
from the Pharmaceutical segment to the Consumer Health segment
based on operational changes in their respective regions
|
|
|
|
|
|
|
(3) Other is inclusive
of PROCRIT / EPREX, which was previously disclosed
separately
|
|
|
|
|
|
|
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-reports-q1-2022-results-301527545.html
SOURCE Johnson & Johnson